Frontier Medicines
Frontier Medicines is a precision medicine company that has pioneered a proprietary discovery and development platform to develop medicines against disease-causing proteins previously considered undruggable. They utilize groundbreaking scientific approaches in chemoproteomics, covalent drug discovery, and machine learning to create innovative therapies, particularly in oncology. Their lead program, FMC-376, targets KRASG12C mutations prevalent in various cancers. Frontier's collaboration with AbbVie aims to develop novel therapies against challenging protein targets, significantly broadening the therapeutic landscape.
Frontier Medicines
Frontier Medicines is a precision medicine company that has pioneered a proprietary discovery and development platform to develop medicines against disease-causing proteins previously considered undruggable. They utilize groundbreaking scientific approaches in chemoproteomics, covalent drug discovery, and machine learning to create innovative therapies, particularly in oncology. Their lead program, FMC-376, targets KRASG12C mutations prevalent in various cancers. Frontier's collaboration with AbbVie aims to develop novel therapies against challenging protein targets, significantly broadening the therapeutic landscape.
TL;DR
Sector: Biotechnology Research — precision small-molecule therapeutics
Platform: Frontier™ platform: chemoproteomics + covalent discovery + machine learning
Lead programs: FMC-376 (KRASG12C, clinical) and FMC-220 (p53 Y220C, preclinical)
Founded: 2018
Known funding (total reported): USD 255,500,000
Offices: South San Francisco and Boston
Related Companies
| Company |
|---|
 |
 |
 |
 |
 |
Company Overview
Problem Domain
Targeting previously undruggable, disease-causing proteins in oncology via covalent small-molecule approaches.
Founded
2018
Industry
Biotechnology Research
Tech Stack
Funding Track Record
67000000 USD
88500000 USD
80000000 USD
Reported as oversubscribed; included strategic investor participation
Investor Signal
“Backed by venture and crossover investors including Deerfield Management, RA Capital, Woodline Partners, MPM Capital, Droia Ventures, DCVC Bio, RA Capital Management, Galapagos, ArrowMark Partners and others”